Table. Seroprevalence of HEV, Papua New Guinea, Fiji, and Kiribati, 2003–2005*.
| Age group, y | Papua New Guinea† |
Fiji† |
Kiribati† |
||||||
|---|---|---|---|---|---|---|---|---|---|
| All | HEV IgG+, % (95% CI) | All | HEV IgG+, % (95% CI) | All | HEV IgG+, % (95% CI) | ||||
| Children | 12/105‡ | 11.4 (6.6–18.9) | 3/91‡ | 3.3 (1.1–9.2) | 12/90 | 13.3 (7.8–21.2) | |||
| <1 | 0/21 | 0 | 1/23 | 4.3 | 1/8 | 12.5 | |||
| 1–<2 | 3/26 | 11.5 | 1/19 | 5.3 | 2/18 | 11.1 | |||
| 2–<5 | 6/24 | 25 | 1/35‡ | 2.9 | 6/48 | 12.5 | |||
| 5–<10 | 1/23‡ | 4.3 | 0/10‡ | 0 | 0/10 | 0 | |||
| 10–<16 | 1/6 | 16.7 | 0/3‡ | 0 | 0/2 | 0 | |||
| Unknown |
1/5 |
20 |
|
0/1 |
0 |
|
3/4 |
75 |
|
| Adults | 71/440 | 16.1 (14.2–21.3) | 3/174 | 1.7 (0.6–4.9) | 9/148 | 6.0 (3.2–11.1) | |||
| 16–19 | 7/24 | 29.2 | 0/8 | 0 | 0/2 | 0 | |||
| 20–29 | 19/162 | 11.7 | 2/76 | 2.6 | 2/61 | 3.3 | |||
| 30–39 | 18/143 | 12.6 | 0/41 | 0 | 3/53 | 3.7 | |||
| 40–49 | 13/70 | 18.6 | 1/28 | 3.6 | 2/19 | 5.3 | |||
| 50–59 | 5/22 | 22.7 | 0/14 | 0 | 2/9 | 22.2 | |||
| 60–69 | 3/7 | 42.9 | 0/5 | 0 | 0/2 | 0 | |||
| 70–79 | 0/4 | 0 | 0/0 | 0 | 0/2 | 0 | |||
| Unknown |
0/9 |
0 |
|
0/1 |
0 |
|
0/0 |
0 |
|
| Total | 83/545‡ | 15.2 (12.5–18.5) | 6/265‡ | 2.3 (1.0–4.9) | 21/238 | 8.8 (5.8–13.1) | |||
*An expanded version of this table that includes sex data is available online (wwwnc.cdc.gov/EID/article/20/7/13-0562-T1.htm). HEV, hepatitis E virus; +, positive. †No. HEV IgG–positive persons/total no. persons in each group. ‡In these groups.